Previous studies have also documented the ameliorative effects of the non-specific AMPK agonists, metformin and AICAR, in mouse models of colitis [15,16,17,18,56,57,58] and possibly a metformin protective effect in human IBD [59]. Here, PRKAA2 is linked to inflammatory bowel disease.